Top

Published in:

01-06-2007 | Case Report

Hepatotoxicity induced by alendronate therapy

Authors: B. Yanık, C. Turkay, H. Atalar

Published in: Osteoporosis International | Issue 6/2007

Abstract

Here we describe a 47-year-old postmenopausal woman who had been taking alendronate 70 mg/week for osteoporosis. After two months of alendronate therapy, she developed hepatotoxicity, and no other etiological factors for this besides the alendronate were apparent. After the alendronate therapy was discontinued, the patient’s hepatic enzyme levels slowly returned to normal. Hepatotoxicity due to alendronate therapy is a rare but possible adverse effect.

Peter C, Rodan GA (1999) Preclinical safety profile of alendronate. Int J Clin Pract Suppl 101:3–8PubMed

Felsenberg D, Alenfeld F, Bock O, Hammermeister C, Gowan W (1998) Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial. Maturitas 31:35–44PubMedCrossRef

Watts N, Freedholm D, Daifotis A (1999) Alendronate: from the laboratory to the patient: the clinical tolerability profile of alendronate. Int J Clin Pract 101:51–61

Eisman JA, Rizzoli R, Roman-Ivorra J, Lipschitz S, Verbruggen N, Gaines KA, Melton ME (2004) Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 20:699–705PubMedCrossRef

Greenspan S, Field-Munves E, Tonino R, Smith M, Petruschke R, Wang L, Yates J, de Papp AE, Palmisano J (2002) Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 77:1044–1052PubMed

Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461–468PubMedCrossRef

Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, Tomita A, Yamamoto K, Nagata Y, Nakashima M, Orimo H (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 10:183–192PubMedCrossRef

Ferrari AP Jr, Domingues SH (1998) Esophageal ulcer and alendronate. Sao Paulo Med J 116:1882–1884CrossRef

Nase JB, Suzuki JB (2006) Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc 137:1115–1119PubMed

10.

Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K (2006) Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 12:48–53PubMed

11.

Coleman CI, Perkerson KA, Lewis A (2004) Alendronate-induced auditory hallucinations and visual disturbances. Pharmacotherapy 24:799–802PubMedCrossRef

12.

Mayoral W, Lewis JH, Zimmerman H (1999) Drug-induced liver disease. Curr Opin Gastroenterol 15:208–216PubMedCrossRef

13.

Lieverse RJ (1998) Hepatitis after alendronate. Neth J Med 53:271–272PubMedCrossRef

14.

Halabe A, Lifschitz BM, Azuri J (2000) Liver damage due to alendronate. N Engl J Med 343:365–366PubMedCrossRef

15.

de La Serna Higuera C, Perez Villoria A, Rodriguez Gomez S, Martinez Moreno J, Betancourt Gonzalez A, Martin Arribas M (2001) Alendronate-induced hepatocellular lesion Gastroenterol Hepatol 24:244–246

16.

Carrere C, Duval JL, Godard B, De Jaureguiberry JP, Ciribilli JM (2002) Severe acute hepatitis induced by alendronate. Gastroenterol Clin Biol 26:179–180PubMed

Title: Hepatotoxicity induced by alendronate therapy
Authors: B. Yanık
C. Turkay
H. Atalar
Publication date: 01-06-2007
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 6/2007
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-007-0323-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Hepatotoxicity induced by alendronate therapy

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2007

Non-compliance: the Achilles' heel of anti-fracture efficacy

Enhanced prediction of fracture risk combining vertebral fracture status and BMD

Concentric and eccentric isokinetic resistance training similarly increases muscular strength, fat-free soft tissue mass, and specific bone mineral measurements in young women

Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation

First meeting on bone quality, Abbaye des Vaux de Cernay, France, 15–16 June 2006: Bone architecture

Letter to editor, Osteoporosis International